10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?
Applied Health Economics and Health Policy, 2023 The German Pharmaceutical Market Restructuring Act (AMNOG, 2011) is a two-stage process to regulate the price of new pharmaceuticals in which price negotiations are conducted based on evidence-based medical benefit assessments using data from prior ...
Melanie Büssgen, T. Stargardt
semanticscholar +1 more source
Analyse des vorläufigen Berichtsplans des Instituts für Qualität und Wirtschaftlichkeit im Gesundheitswesen für eine Kosten-Nutzen-Bewertung zu Clopidogrel bei der peripheren arteriellen Verschlusskrankheit und beim akuten Koronarsyndrom [PDF]
, 2010 --
Aidelsburger, Pamela, Wasem, Jürgen
core +3 more sources
Deutsches Ärzteblatt International, 2023 BACKGROUND Persons with a positive family history of colorectal cancer (CRC) are more likely than others to develop CRC and are also younger at the onset of the disease.
Alexander Crispin +9 more
semanticscholar +1 more source
Published and unpublished evidence in coverage decision-making for pharmaceuticals in Europe: existing approaches and way forward [PDF]
, 2016 List of regulatory documents organized per country and list of publications.
Alexandra Nolting +4 more
core +7 more sources
Neugeborenen-Hörscreening in Deutschland – Ergebnisse der Evaluationen 2011/2012 und 2017/2018
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2023 Background Newborn hearing screening (NHS) was introduced nationwide by the Federal Joint Committee (Gemeinsamer Bundesausschuss, G‑BA) in 2009. In this process, quality targets were also set in the pediatrics directive.
Inken Brockow +8 more
semanticscholar +1 more source
A systematic review of health economic models of opioid agonist therapies in maintenance treatment of non-prescription opioid dependence [PDF]
, 2017 Background: Opioid dependence is a chronic condition with substantial health, economic and social costs. The study objective was to conduct a systematic review of published health-economic models of opioid agonist therapy for non-prescription opioid ...
Chetty, Mersha +4 more
core +8 more sources
The German health care Innovation Fund – An incentive for innovations to promote the integration of health care [PDF]
, 2021 Purpose – Many health systems face challenges such as rising costs and lacking quality, both of which can be addressed by improving the integration of different health care sectors and professions.
Auschra, Carolin +5 more
core +1 more source
Naunyn-Schmiedeberg's Archives of Pharmacology, 2023 The prices of oncology drugs have been rising progressively in recent years. Despite accounting for only a small share of prescriptions, oncology drugs are the most expensive drugs on the market.
Caecilia S. Obst, R. Seifert
semanticscholar +1 more source
The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe [PDF]
, 2016 Background The aim of this study was to review and compare types of reimbursement recommendations for orphan drugs issued by eight European health technology assessment (HTA) agencies and the reimbursement status of these drugs in the corresponding ...
Kawalec, Paweł +2 more
core +2 more sources
Value in Health, 2022 This article discusses a recent methodological change to assess the additional benefit of drug intervention by the German Federal Joint Committee (Gemeinsamer Bundesausschuss), a key stakeholder in EUnetHTA21 (European Network for Health Technology ...
M. Schlichting +8 more
semanticscholar +1 more source